In my view, the contemplated merger is not in the best interest of SKTO, the mother ship and vessel holding Berkeley Bio, SKTO's crown jewel. The bewildering erraticism of the cast of shawdowy characters at AEGY who cyclically appear and disappear like the morning dew is a red flag to regulators. To any outside observer, it would appear that they periodically draw their sometimes misspelled or obfuscated names out of a hat and whimsically assign these names to key positions at the firm. Additionally stigmatized by obscene levels of convertible debt, AEGY seems lost as a credible public company. SKTO's best course, in my view, is to make tracks away from that firm because SKTO has too many good things in its favor right now.